- call +1-201-465-4211
- email sales@mrinsights.biz
Acetylcholine esterase (AChE) inhibitors are considered to be the basic treatment of myasthenia gravis (MG). Edrophonium is primarily used as a diagnostic tool owing to its short half-life. Pyridostigmine is used for long-term maintenance.
Scope of the Report:
This report focuses on the Myasthenia Gravis Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The market is witnessing the rapid development of novel drugs such as monoclonal antibodies, which is one of the primary factors driving this market’s growth prospects. Most drug manufacturers are increasingly focussing on the development of monoclonal antibodies, as they act specifically on target cells; thereby, leading to lower side effects. Since conventional therapies such as acetylcholinesterase inhibitor, oral steroids, and immunomodulatory agents are associated with more side effects, physicians prefer to prescribe high efficacious monoclonal antibodies.
The worldwide market for Myasthenia Gravis Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Flamel Technologies
Roche
Grifols
Pfizer
Shire
Novartis
Valeant
Alexion
Catalyst
CSL
Curavac
Cytokinetics
Galencia
GlaxoSmithKline
Lupin Pharmaceuticals
Mitsubishi Tanabe Pharma
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Anticholinesterases
Immunosuppressants
Intravenous Immune Globulins
Market Segment by Applications, can be divided into
Hospitals
Clinics
There are 15 Chapters to deeply display the global Myasthenia Gravis Drugs market.
Chapter 1, to describe Myasthenia Gravis Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Myasthenia Gravis Drugs, with sales, revenue, and price of Myasthenia Gravis Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Myasthenia Gravis Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Myasthenia Gravis Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Myasthenia Gravis Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Myasthenia Gravis Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Anticholinesterases
1.2.2 Immunosuppressants
1.2.3 Intravenous Immune Globulins
1.3 Market Analysis by Applications
1.3.1 Hospitals
1.3.2 Clinics
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Flamel Technologies
2.1.1 Business Overview
2.1.2 Myasthenia Gravis Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Flamel Technologies Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Roche
2.2.1 Business Overview
2.2.2 Myasthenia Gravis Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Roche Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Grifols
2.3.1 Business Overview
2.3.2 Myasthenia Gravis Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Grifols Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Pfizer
2.4.1 Business Overview
2.4.2 Myasthenia Gravis Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Pfizer Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Shire
2.5.1 Business Overview
2.5.2 Myasthenia Gravis Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Shire Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Novartis
2.6.1 Business Overview
2.6.2 Myasthenia Gravis Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Novartis Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Valeant
2.7.1 Business Overview
2.7.2 Myasthenia Gravis Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Valeant Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Alexion
2.8.1 Business Overview
2.8.2 Myasthenia Gravis Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Alexion Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Catalyst
2.9.1 Business Overview
2.9.2 Myasthenia Gravis Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Catalyst Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 CSL
2.10.1 Business Overview
2.10.2 Myasthenia Gravis Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 CSL Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Curavac
2.11.1 Business Overview
2.11.2 Myasthenia Gravis Drugs Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Curavac Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 Cytokinetics
2.12.1 Business Overview
2.12.2 Myasthenia Gravis Drugs Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Cytokinetics Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 Galencia
2.13.1 Business Overview
2.13.2 Myasthenia Gravis Drugs Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Galencia Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.14 GlaxoSmithKline
2.14.1 Business Overview
2.14.2 Myasthenia Gravis Drugs Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 GlaxoSmithKline Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.15 Lupin Pharmaceuticals
2.15.1 Business Overview
2.15.2 Myasthenia Gravis Drugs Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.16 Mitsubishi Tanabe Pharma
2.16.1 Business Overview
2.16.2 Myasthenia Gravis Drugs Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Myasthenia Gravis Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Myasthenia Gravis Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Myasthenia Gravis Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Myasthenia Gravis Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Myasthenia Gravis Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Myasthenia Gravis Drugs Market Analysis by Regions
4.1 Global Myasthenia Gravis Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Myasthenia Gravis Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Myasthenia Gravis Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
4.5 South America Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
5 North America Myasthenia Gravis Drugs by Countries
5.1 North America Myasthenia Gravis Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Myasthenia Gravis Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Myasthenia Gravis Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
6 Europe Myasthenia Gravis Drugs by Countries
6.1 Europe Myasthenia Gravis Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Myasthenia Gravis Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Myasthenia Gravis Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
6.3 UK Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
6.4 France Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Myasthenia Gravis Drugs by Countries
7.1 Asia-Pacific Myasthenia Gravis Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Myasthenia Gravis Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Myasthenia Gravis Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
7.5 India Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
8 South America Myasthenia Gravis Drugs by Countries
8.1 South America Myasthenia Gravis Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Myasthenia Gravis Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Myasthenia Gravis Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Myasthenia Gravis Drugs by Countries
9.1 Middle East and Africa Myasthenia Gravis Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Myasthenia Gravis Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Myasthenia Gravis Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Myasthenia Gravis Drugs Sales and Growth Rate (2013-2018)
10 Global Myasthenia Gravis Drugs Market Segment by Type
10.1 Global Myasthenia Gravis Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Myasthenia Gravis Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Myasthenia Gravis Drugs Revenue and Market Share by Type (2013-2018)
10.2 Anticholinesterases Sales Growth and Price
10.2.1 Global Anticholinesterases Sales Growth (2013-2018)
10.2.2 Global Anticholinesterases Price (2013-2018)
10.3 Immunosuppressants Sales Growth and Price
10.3.1 Global Immunosuppressants Sales Growth (2013-2018)
10.3.2 Global Immunosuppressants Price (2013-2018)
10.4 Intravenous Immune Globulins Sales Growth and Price
10.4.1 Global Intravenous Immune Globulins Sales Growth (2013-2018)
10.4.2 Global Intravenous Immune Globulins Price (2013-2018)
11 Global Myasthenia Gravis Drugs Market Segment by Application
11.1 Global Myasthenia Gravis Drugs Sales Market Share by Application (2013-2018)
11.2 Hospitals Sales Growth (2013-2018)
11.3 Clinics Sales Growth (2013-2018)
12 Myasthenia Gravis Drugs Market Forecast (2018-2023)
12.1 Global Myasthenia Gravis Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Myasthenia Gravis Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Myasthenia Gravis Drugs Market Forecast (2018-2023)
12.2.2 Europe Myasthenia Gravis Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Myasthenia Gravis Drugs Market Forecast (2018-2023)
12.2.4 South America Myasthenia Gravis Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Myasthenia Gravis Drugs Market Forecast (2018-2023)
12.3 Myasthenia Gravis Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Myasthenia Gravis Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Myasthenia Gravis Drugs Market Share Forecast by Type (2018-2023)
12.4 Myasthenia Gravis Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Myasthenia Gravis Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Myasthenia Gravis Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Myasthenia Gravis Drugs Picture
Table Product Specifications of Myasthenia Gravis Drugs
Figure Global Sales Market Share of Myasthenia Gravis Drugs by Types in 2017
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
